AI assistant
Transgene Investor Presentation 2021
1715_iss_2021-09-13_3f929314-6345-4304-a228-24855c91e457.pdf
Investor Presentation
Open in viewerOpens in your device viewer
Transgene Announces Upcoming Investor Meetings
Strasbourg, France, September 13, 2021, 08:00 am CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that Management will participate in the upcoming investor events set out below: - Investor Access Forum – Physical event (Paris, France)
- September 27 & 28, 2021 HealthTech Innovation Days 2021 Digital & physical event (Paris, France) October 4 & 5, 2021 - European Midcap Event – Digital & physical event (Paris, France)
- October 21 & 22, 2021 EigenKapitalForum Digital event
- November 22, 2021 Investor Day Physical event (Paris, France) November 23, 2021
Next scheduled financial communication
First Half 2021 Financial Results September 22, 2021, after trading hours – The company will host a conference call at 6:00 pm CET
***
About Transgene
Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.
The Company's clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the myvac® platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO™ platform).
With Transgene's myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO™, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO™ collaboration with AstraZeneca. Additional information about Transgene is available at: www.transgene.fr.// Follow us on Twitter: @TransgeneSA
Contacts
Transgene: Lucie Larguier Director Corporate Communications & IR +33 (0)3 88 27 91 04 [email protected]
Media: MEDiSTRAVA Consulting David Dible/Sylvie Berrebi +44 (0)77 1430 6525 [email protected]
